Thanks to emma margaret atkinson University of Denver for featuring my work defining health care affordability on #RadioEd! I analyze health affordability in depth in my "Defining Health Affordability," available open access Iowa Law Review: ilr.law.uiowa.edu/volume-109-iss…

For Obese Patients, Wegovy Is Worth the Cost by Govind Persad (also @govindpersad.bsky.social) and Zeke Emanuel wsj.com/articles/for-o… via Wall Street Journal Opinion

In my latest for The Wall Street Journal, Govind Persad (also @govindpersad.bsky.social) & I argue that North Carolina’s decision to deny coverage for GLP-1 drugs like #ozempic for individuals with obesity is both unethical and short-sighted. Read below ⬇️ 1/4 wsj.com/articles/for-o…

"Coverage for weight-loss drugs could reduce obesity immediately while less consumption of harmful foods could help prevent it. Fewer people would need expensive treatments like Wegovy in the longer term." Govind Persad (also @govindpersad.bsky.social) & Zeke Emanuel via Wall Street Journal Opinion wsj.com/articles/for-o…

Association of Race and Ethnicity With High Longevity Deceased Donor Kidney Transplantation Under the US Kidney Allocation System buff.ly/3QiZAF2 Peter Reese Milda Saunders @DrMonicaPeek Govind Persad (also @govindpersad.bsky.social) William F Parker, MD, PhD University of Chicago Nephrology

Our article, Bioethicists Today: Results of the Views in Bioethics Survey (VIBeS), is now out in AJOB! We surveyed 824 US bioethicists on: (1) Major issues in bioethics, like medical aid in dying, paying organ donors, abortion, and many others (2) Their backgrounds 🧵

There are many more results in the paper, so check it out! tandfonline.com/doi/full/10.10… (Feel free to email/DM me if you can't access it.) And a huge shout out to the whole VIBES team: Sophie Gibert, Leila Orszag, @_Haley_Sullivan, Rachel Fei, Govind Persad (also @govindpersad.bsky.social), and Emily Largent.

Govind Persad, JD, PhD, on Understanding the Legal and Ethical Challenges AI Poses in Oncology ascopost.com/issues/may-25-… #oncology #AI Govind Persad (also @govindpersad.bsky.social)

Despite the efficacy of GLP-1s in treating obesity, the high cost of these drugs pose significant challenges for public health systems worldwide. In The Lancet, Johan Dellgren, Govind Persad (also @govindpersad.bsky.social), and I look at the limitations and the promises of GLP-1s. thelancet.com/journals/lance…